点击蓝字关注我们编者按2025年欧洲肿瘤内科学会年会(ESMO 2025)将于10月17~21日在德国柏林盛大举行。作为全球肿瘤学领域最具影响力的学术盛会之一,本届大会将集中呈现肿瘤诊疗领域的突破性研究进展。目前,大会官网已公布除LBA(Late-breaking Abstract)摘要外的全部入选研究标题。本文系统梳理了消化系统肿瘤领域Proffered Paper session和Mini oral session部分前沿成果,涵盖结直肠癌、胃癌、肝癌、胰腺癌、神经内分泌肿瘤等主要癌种,旨在为临床工作者和研究人员构建完整的研究进展图谱。期待ESMO 2025正式召开时,更多重磅数据的发布有望为全球消化系统肿瘤诊疗实践带来革命性突破。上消化道肿瘤Proffered Paper session 摘要号:2094O英文标题:SKYSCRAPER-07: A phase Ⅲ, randomised study of atezolizumab (atezo) with or without tiragolumab (tira) in patients (pts) with unresectable esophageal squamous cell carcinoma (ESCC) that has not progressed following definitive concurrent chemoradiotherapy (dCRT)中文标题:SKYSCRAPER-07:阿替利珠单抗(Atezo)联合或不联合Tiragolumab(Tira)治疗接受过根治性同步放化疗(dCRT)后未进展的不可切除食管鳞癌(ESCC)患者的Ⅲ期随机研究讲者:Ian Chau (Sutton, United Kingdom)Mini oral session 摘要号:2095MO 英文标题:Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive localized esophagogastric adenocarcinoma – Interim Analysis of the phase Ⅱ PHERFLOT/IKF-053 trial of the AIO study group (AIO STO 0321)中文标题:帕博利珠单抗联合曲妥珠单抗及FLOT方案用于HER2阳性局部食管胃腺癌围手术期治疗——AIO研究组Ⅱ期PHERFLOT/IKF-053试验的阶段性分析(AIO STO 0321)讲者:Eray Goekkurt (Hamburg, Germany)***************************************************************摘要号:2096MO英文标题:Systemic Therapy, Gastrectomy and CRS/HIPEC vs Systemic Therapy Alone for Gastric Cancer with Limited Peritoneal Dissemination: Results of the Randomised PERISCOPE Ⅱ Trial.中文标题:系统治疗、胃切除术联合CRS/HIPEC对比单纯系统治疗用于局限性腹膜播散胃癌:随机化PERISCOPE Ⅱ试验结果讲者:Judith S. Quik (Amsterdam, Netherlands)***************************************************************摘要号:1469MO英文标题:Liver resection versus continued atezolizumab plus bevacizumab (atezo/bev) in locally advanced hepatocellular carcinoma (HCC) after atezo/bev treatment (TALENTop): a multicenter, open-label, randomized phase Ⅲ trial.中文标题:局部晚期肝细胞癌(HCC)患者接受Atezo/Bev治疗后,肝切除术对比继续Atezo/Bev治疗(TALENTop):多中心、开放标签、随机Ⅲ期试验讲者:Hui-Chuan Sun (Shanghai, China)讲者:复旦大学附属中山医院 孙惠川***************************************************************摘要号:1470MO英文标题:Perioperative Camrelizumab plus Rivoceranib in Resectable Hepatocellular Carcinoma (CARES-009): A Randomized, Multicenter, Phase 3 Trial中文标题:围手术期卡瑞利珠单抗联合瑞戈非尼治疗可切除肝细胞癌(CARES-009):随机、多中心、Ⅲ期试验讲者:复旦大学附属中山医院 周俭***************************************************************摘要号:1471MO英文标题:Adding Ipilimumab (IPI) to Atezolizumab (ATEZO) plus Bevacizumab (BEV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in first-line systemic therapy (1L): PRODIGE 81/FFCD 2101 - TRIPLET HCC中文标题:伊匹木单抗(IPI)联合阿替利珠单抗(ATEZO)和贝伐珠单抗(BEV)用于不可切除肝细胞癌(uHCC)的一线系统治疗(1L):PRODIGE 81/FFCD 2101 - TRIPLET HCC试验讲者:Philippe Merle (LYON, France)***************************************************************摘要号:2214MO 英文标题:Phase 1 basket study of telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein–targeting antibody-drug conjugate: Results from patients (pts) with pancreatic ductal adenocarcinoma (PDAC)中文标题:针对c-Met蛋白的抗体药物偶联物Telisotuzumab Adizutecan(ABBV-400; Temab-A)的Ⅰ期篮式研究:胰腺导管腺癌(PDAC)患者的结果讲者:James J. Harding (New York, United States of America)***************************************************************摘要号:2215MO英文标题:HRS-4642 Combined with Gemcitabine and Nab-paclitaxel in KRAS-G12D Mutant Advanced Pancreatic Cancer: A Phase 1b/2 Study中文标题:HRS-4642联合吉西他滨和白蛋白结合型紫杉醇治疗KRAS-G12D突变晚期胰腺癌:1b/2期研究讲者:上海交通大学医学院附属仁济医院 王理伟教授***************************************************************摘要号:2216MO英文标题:VIRAGE trial: randomized Phase Ⅱb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic Cancer (mPDAC)中文标题:VIRAGE试验:随机Ⅱb期、开放标签研究,评估白蛋白结合型紫杉醇联合吉西他滨±静脉VCN-01治疗转移性胰腺癌(mPDAC)讲者:Rocio Garcia-Carbonero (Madrid, Spain)下消化道肿瘤Proffered paper session摘要号:726O英文标题:Prognostic value of the Combined Analysis of Pathologists and Artificial Intelligence (CAPAI) in high-risk stage Ⅱ-Ⅲ colon cancer treated without chemotherapy: interim report from a nationwide validation中文标题:病理学家与人工智能联合分析(CAPAI)对未接受化疗的高危Ⅱ-Ⅲ期结肠癌的预后价值:全国验证的阶段性报告讲者:Marie-Christine E. Bakker (Utrecht, Netherlands)***************************************************************摘要号:723O英文标题:Post-surgical liquid biopsy-guided treatment of stage Ⅲ and high-risk stage Ⅱ colon cancer patients: final results of the PEGASUS trial.中文标题:术后液体活检指导的Ⅲ期及高危Ⅱ期结肠癌治疗:PEGASUS试验最终结果讲者:Silvia Marsoni (Milan, Italy, (TO))***************************************************************摘要号:724O英文标题:Comparison of outcomes in clinical trials of locally advanced dMMR colon cancer: FOxTROT and NICHE-2中文标题:局部晚期dMMR结肠癌临床试验结果比较:FOxTROT与NICHE-2讲者:Jenny Seligmann (Leeds, United Kingdom, Yorkshire)***************************************************************摘要号:725O英文标题:Leveraging Artificial Intelligence to predict immune checkpoint inhibitor (ICI) efficacy in proficient MMR mCRC: translational analyses of AtezoTRIBE and AVETRIC trials中文标题:利用人工智能预测免疫检查点抑制剂(ICI)在MMR熟练型转移性结直肠癌(mCRC)中的疗效:AtezoTRIBE和AVETRIC试验的转化分析讲者:Martina Carullo (Pisa, Italy)Mini oral session摘要号:1MO英文标题:Placental features overexpression reveals hidden facets of early-onset colorectal cancer中文标题:胎盘特征过度表达揭示早发性结直肠癌的隐藏面讲者:Gianluca Mauri (Milan, Italy)***************************************************************摘要号:727MO英文标题:FOLFOX plus PANITUMUMAB (Pmab) according to a “stop-and-go” strategy in first-line in patients (pts) with non-mutated RAS/BRAF metastatic colorectal cancer (mCRC). Results of the FFCD 1605 – OPTIPRIME phase Ⅱ trial.中文标题: FOLFOX联合帕尼单抗(Pmab)"stop-and-go"策略治疗RAS/BRAF野生型转移性结直肠癌(mCRC)患者的一线治疗:FFCD 1605-OPTIPRIME Ⅱ期试验结果讲者:Jean-Baptiste Bachet (Paris, France)***************************************************************摘要号:728MO英文标题:Predictive Value of Low-Frequency Resistance Mutations and Relative Mutant Allele Frequencies (rMAFs) in Anti-EGFR Rechallenge for RAS/BRAF Wild-Type (wt) Metastatic Colorectal Cancer (mCRC)中文标题:低频耐药突变及相对突变等位基因频率(rMAFs)在RAS/BRAF野生型转移性结直肠癌(mCRC)抗EGFR再挑战中的预测价值讲者:Pau Mascaró Baselga (Barcelona, Spain)***************************************************************摘要号:729MO英文标题:Circulating tumor (ct) DNA analysis of BRAF V600E dynamics and changes in genomic landscape in patients (pts) with first-line (1L) BRAF V600E-mutant metastatic colorectal cancer (mCRC) treated in BREAKWATER中文标题:循环肿瘤(ct)DNA分析BRAF V600E动态及基因组图谱变化:BREAKWATER试验中一线(1L)BRAF V600E突变转移性结直肠癌(mCRC)患者讲者:Scott Kopetz (Houston, United States of America)***************************************************************摘要号:730MO英文标题:Trifluridine/Tipiracil in combination with Capecitabine and Bevacizumab as upfront treatment for metastatic colorectal cancer: first results of the phase Ⅱ TriComB study by GONO中文标题:曲氟尿苷/替匹嘧啶联合卡培他滨和贝伐珠单抗作为转移性结直肠癌的初始治疗:GONO Ⅱ期TriComB研究的初步结果讲者:Veronica Conca (Pisa, Italy)***************************************************************摘要号:731MO英文标题:Telisotuzumab adizutecan (ABBV-400; Temab-A) in combination with bevacizumab (Bev) vs standard of care (SOC) in patients (pts) with 3L+ colorectal cancer (CRC): Dose expansion results of a phase 1 study中文标题:Telisotuzumab Adizutecan(ABBV-400; Temab-A)联合贝伐珠单抗(Bev)对比标准治疗(SOC)用于3线及以上结直肠癌(CRC):Ⅰ期研究剂量扩展结果讲者:Michael Cecchini (New Haven, United States of America)神经内分泌肿瘤与内分泌肿瘤Proffered Paper session摘要号:1705O英文标题:LITESPARK-015: Belzutifan in advanced pheochromocytoma and paraganglioma中文标题:LITESPARK-015:Belzutifan治疗晚期嗜铬细胞瘤和副神经节瘤讲者:Camilo Jimenez (Houston, United States of America)***************************************************************摘要号:1706O英文标题:Efficacy, safety and subgroup analysis of 177Lu-edotreotide vs everolimus in patients with Grade 1 or Grade 2 GEP-NETs: Phase 3 COMPETE trial中文标题:177Lu-edotreotide对比依维莫司治疗1~2级胃肠胰神经内分泌肿瘤(GEP-NETs)的疗效、安全性及亚组分析:Ⅲ期COMPETE试验讲者:Jaume Capdevila (Barcelona, Spain)***************************************************************摘要号:2987O英文标题:Efficacy and Safety of Dabrafenib Plus Trametinib (D+T) in Patients With Radioactive Iodine (RAI)-Refractory BRAF V600-Mutant Differentiated Thyroid Cancer (DTC)中文标题:达拉非尼联合曲美替尼(D+T)治疗放射性碘(RAI)难治性BRAF V600突变分化型甲状腺癌(DTC)的疗效与安全性讲者:津市人民医院 高明教授Mini oral session摘要号:1707MO英文标题:A Phase 2 Dose Expansion Study of ZG006, a Trispecific T Cell Engager Targeting DLL3/DLL3/CD3, as Monotherapy in Patients with Refractoy Neuroendocrine Carcinoma中文标题:ZG006(靶向DLL3/DLL3/CD3的三特异性T细胞衔接器)单药治疗难治性神经内分泌癌的Ⅱ期剂量扩展研究讲者:中国人民解放军总医院 赵传华***************************************************************摘要号:1708MO英文标题:ZG005 in combination with etoposide and cisplatin for the first-line treatment of advanced neuroendocrine carcinoma中文标题:ZG005联合依托泊苷和顺铂用于晚期神经内分泌癌的一线治疗讲者:Sisi Ye (Beijing, China)***************************************************************摘要号:1709MO英文标题:Multi-center NCI-sponsored phase 1 study of triapine in combination with 177Lu-dotatate in patients with well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs)中文标题:多中心NCI资助的Ⅰ期研究:Triapine联合177Lu-dotatate治疗分化良好的胃肠胰神经内分泌肿瘤(GEP-NETs)讲者:Aman Chauhan (Deerfield Beach, United States of America)***************************************************************摘要号:1033MO英文标题:[212Pb]VMT-α-NET targeted alpha-particle therapy (TAT) for advanced somatostatin receptor 2 positive (SSTR2+) neuroendocrine tumours (NETs): mature safety and preliminary efficacy for enrollment from dose-finding cohorts 1 and 2 (n=44)中文标题:[212Pb]VMT-α-NET靶向α粒子治疗(TAT)用于晚期生长抑素受体2阳性(SSTR2+)神经内分泌肿瘤(NETs):剂量探索队列1和2(n=44)的成熟安全性和初步疗效讲者:Thorvardur R. Halfdanarson (Rochester, United States of America)***************************************************************摘要号:1034MO英文标题:Long-term Follow-up of Peptide Receptor Radionuclide Therapy (PRRT)-Naïve Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) Treated with Targeted Alpha Therapy 212Pb-DOTAMTATE in the Phase 2 ALPHAMEDIX 02 Trial中文标题:212Pb-DOTAMTATE靶向α治疗在未接受过肽受体放射性核素治疗(PRRT)的胃肠胰腺神经内分泌肿瘤(GEP-NETs)患者中的长期随访:一项Ⅱ期ALPHAMEDIX 02临床试验结果讲者:Jonathan R. Strosberg (Tampa, United States of America)***************************************************************摘要号:1035MO英文标题:A Prediction Tool for Malnutrition and Sarcopenia in Patients with Gastroenteropancreatic (GEP) Neuroendocrine Neoplasms (NENs): Results from NUTRIGETNE (GETNE-S2109) Study中文标题:胃肠胰神经内分泌肿瘤(NENs)患者营养不良和肌肉减少症的预测工具:NUTRIGETNE(GETNE-S2109)研究结果讲者:Maribel Del Olmo (Valencia, Spain)***************************************************************摘要号:1710MO英文标题:Belzutifan for Advanced Pancreatic Neuroendocrine Tumors (panNETs): Results From Cohort A2 of the Phase 2 LITESPARK-015 Study中文标题:Belzutifan治疗晚期胰腺神经内分泌肿瘤(panNETs):Ⅱ期LITESPARK-015研究A2队列结果讲者:Jaume Capdevila (Barcelona, Spain)***************************************************************摘要号:2988MO英文标题:Patient-Derived Organoids Predict Clinical Response and Guide Personalized Therapy in Advanced Thyroid Cancer中文标题:患者来源的类器官预测晚期甲状腺癌临床反应并指导个性化治疗讲者:Jiaye Liu (Chengdu, China)(来源:肿瘤瞭望消化时讯)声 明凡署名原创的文章版权属《肿瘤瞭望》所有,欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用,不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导,也不应被视为诊疗建议,如果该信息被用于资讯以外的目的,本站及作者不承担相关责任。